Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients

Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2019-01, Vol.11 (1), p.93
Hauptverfasser: van der Sijde, Fleur, Vietsch, Eveline E, Mustafa, Dana A M, Besselink, Marc G, Groot Koerkamp, Bas, van Eijck, Casper H J
Format: Artikel
Sprache:eng
Schlagworte:
Antigens
Biomarkers
Biopsy
Chemotherapy
Clinical trials
Gemcitabine
Medical research
Metastasis
Mortality
Pancreatic cancer
Patients
Response rates
Review
Toxicity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive care, many individual patients may not benefit from chemotherapy. Biomarkers are needed to predict who will benefit from chemotherapy and to monitor a patient's response to chemotherapy. This review summarizes current research and future perspectives on circulating biomarkers for systemic chemotherapy response.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11010093